Advertisement
BLFS vs EMBC
Which Stock Would AI Choose? BioLife Solutions (BLFS) vs. Embecta (EMBC) Stock Comparison
Key Takeaways
- BLFS trades at around $21 with a $1.04B market cap, showing YTD gains of 11.56% amid growth in cell and gene therapy (CGT) bioproduction tools.
- EMBC is at approximately $4 with a $230M market cap, experiencing sharp declines post-Q2 earnings miss, despite larger $1.08B TTM revenue.
- BLFS reports 29% full-year 2025 revenue growth to $96M, with upcoming Q1 2026 results on May 7; profitability challenged but improving margins.
- EMBC saw Q2 FY2026 revenue drop 14% to $222M, lowered FY guidance, but maintains strong historical margins around 13%.
- Both in medical devices, BLFS offers higher growth potential in CGT, while EMBC faces U.S. diabetes care headwinds from pricing and competition.
- Tickeron’s AI tools highlight relative momentum favoring BLFS in recent market activity.
Introduction
This stock comparison examines BioLife Solutions (BLFS) and Embecta (EMBC), two players in the medical devices sector. BLFS focuses on biopreservation for cell and gene therapies, while EMBC specializes in diabetes injection devices. Traders seeking growth in biotech innovation or value in established medtech, and investors tracking relative performance and market positioning, will find value here. Recent earnings and sector dynamics underscore contrasts in momentum and risk, aiding decisions on stock comparison amid volatile healthcare trends.
BLFS Overview and Recent Performance
BioLife Solutions (BLFS), headquartered in Bothell, Washington, develops biopreservation media, cell processing tools, and shipping solutions for the cell and gene therapy (CGT) industry. Its products like CryoStor and HypoThermosol address preservation challenges in biologics manufacturing.
In recent market activity, BLFS shares have shown resilience, up 11.56% YTD and 11.63% over one year, trading around $21 with a $1.04B market cap. Full-year 2025 revenue grew 29% to $96.2M, with Q4 up 20%, driven by biopreservation media strength and strategic divestitures focusing on high-margin CGT tools. Analysts note undervaluation potential, with gross margins at 64% and upcoming Q1 2026 earnings on May 7. Sentiment benefits from CGT sector tailwinds, though high beta (1.97) reflects volatility; recent weeks saw modest gains amid broader healthcare rotation.
EMBC Overview and Recent Performance
Embecta (EMBC), based in Parsippany, New Jersey, provides insulin pens, syringes, and safety devices for diabetes management, selling primarily to wholesalers globally.
Recent performance has pressured EMBC, with shares around $4 and $230M market cap after a post-Q2 plunge. YTD return stands at 66.77%, but one-year at 67.13% masks recent weakness; Q2 FY2026 revenue fell 14.4% to $221.8M, missing estimates, with U.S. pen needle share loss and pricing hits prompting lowered FY guidance to $1.015B-$1.035B. TTM revenue is $1.08B with 12.92% profit margins and low PE (1.65), but negative ROE signals leverage risks (high debt). International growth offsets some U.S. softness; pending Owen Mumford acquisition aims at diversification, influencing cautious sentiment in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots out of 351 total bots, curated by AI for current market conditions. These bots trade thousands of tickers across stocks, ETFs, and crypto using diverse strategies like momentum, sector rotation, and trend analysis on timeframes from 5 minutes to daily. Top performers boast annualized returns up to 162%, win rates of 50-75%, and profit factors of 1.5-3.3, such as semiconductor bots at +96% return (63% win rate) or small-cap trend traders at +92% (58% win rate). With hundreds of AI bots available—many delivering 70-80% win rates and up to 3.0+ profit factors—the trending section highlights the most suitable for today’s volatility in semis, energy, and tech. Explore these for copy trading signals tailored to real-time opportunities.
Head-to-Head Comparison
BLFS and EMBC operate in medical instruments but diverge sharply: BLFS’s CGT bioproduction model targets high-growth biologics (29% revenue rise), contrasting EMBC’s mature diabetes franchise facing GLP-1 competition and U.S. pricing erosion.
Momentum favors BLFS with stable recent gains versus EMBC’s earnings-driven drop. Risks include BLFS’s losses (-4.78% margins, high beta 1.97) and CGT delays, while EMBC offers profitability (13% margins) but high debt and lowered outlook. Sector exposure: BLFS rides biotech expansion; EMBC contends with medtech peers’ stability. Valuation tilts value to EMBC (low PE), growth to BLFS; sentiment shifts positive for BLFS on catalysts like earnings.
Tickeron AI Verdict
Tickeron’s AI would currently favor BioLife Solutions (BLFS) over Embecta (EMBC). Observable factors include BLFS’s trend consistency in CGT growth, upcoming earnings catalyst, and relative stability versus EMBC’s post-earnings volatility and guidance cut. With stronger momentum and sector tailwinds, BLFS shows higher probabilistic upside in the near term, though both carry sector risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Hold and EMBC is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLFS’s FA Score shows that 1 FA rating(s) are green whileEMBC’s FA Score has 2 green FA rating(s).
- BLFS’s FA Score: 1 green, 4 red.
- EMBC’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLFS’s TA Score shows that 6 TA indicator(s) are bullish while EMBC’s TA Score has 5 bullish TA indicator(s).
- BLFS’s TA Score: 6 bullish, 4 bearish.
- EMBC’s TA Score: 5 bullish, 5 bearish.
Price Growth
BLFS (@Pharmaceuticals: Other) experienced а +2.99% price change this week, while EMBC (@Pharmaceuticals: Other) price change was -63.68% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.08%. For the same industry, the average monthly price growth was +3.59%, and the average quarterly price growth was +23.30%.
Reported Earning Dates
BLFS is expected to report earnings on Aug 06, 2026.
EMBC is expected to report earnings on Aug 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.08% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BLFS | EMBC | BLFS / EMBC | |
| Capitalization | 1.08B | 199M | 541% |
| EBITDA | -12.07M | 312M | -4% |
| Gain YTD | -10.174 | -71.306 | 14% |
| P/E Ratio | N/A | 1.78 | - |
| Revenue | 102M | 1.04B | 10% |
| Total Cash | 81M | 185M | 44% |
| Total Debt | 14.9M | 1.36B | 1% |
BLFS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 91 | |
PRICE GROWTH RATING 1..100 | 54 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BLFS | EMBC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| Advances ODDS (%) | 6 days ago 76% | 5 days ago 77% |
| Declines ODDS (%) | 2 days ago 84% | 7 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 66% |
Advertisement
EMBC and
Correlation & Price change
A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with BLFS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To EMBC | 1D Price Change % | ||
|---|---|---|---|---|
| EMBC | 100% | -7.69% | ||
| BLFS - EMBC | 43% Loosely correlated | -1.45% | ||
| WAT - EMBC | 37% Loosely correlated | -1.99% | ||
| MTD - EMBC | 37% Loosely correlated | -4.08% | ||
| AVTR - EMBC | 37% Loosely correlated | -4.09% | ||
| RVTY - EMBC | 36% Loosely correlated | -2.03% | ||
More | ||||